Scrying Biotech
Long only, biotech, micro-cap, small-cap

Nektar Therapeutics Is The Seattle Genetics Of San Francisco But It Could Be More

The most extraordinary thing happened to me while researching this article. I listen to dozens of corporate presentations each month while researching my investment possibilities (which must be added to the list of things terribly wrong with me - because I actually enjoy them) but this is the wackiest thing I've ever heard.

Here's Nektar (NASDAQ:NKTR) president, Howard Robin at the 32nd Annual J.P. Morgan Healthcare Conference just one week ago.

So, I think Nektar is very well positioned to move towards a positive cash flow. If you look at what we have either in Phase 3, or filed programs, it's pretty impressive. In Phase 3 we have Amikacin Inhale, and I'll talk about some of these today,...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details